Skip to content

Biological Evaluation of Orthopedic Materials: An In Vitro Study Using Patient-Derived Human Samples

Biological Evaluation of Orthopedic Materials: An In Vitro Study Using Patient-Derived Human Samples

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07671521
Acronym
RAISE
Enrollment
50
Registered
2026-06-26
Start date
2026-09-01
Completion date
2028-06-01
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytotoxicity

Brief summary

The anterior cruciate ligament (ACL) is the primary stabilizer of the knee joint, and ACL injuries are highly prevalent, particularly among physically active and athletic individuals. Although ACL reconstruction is a well-established orthopedic procedure, significant challenges remain regarding biological integration between the graft and bone, which may negatively affect clinical outcomes. In recent years, advanced biomaterials and regenerative medicine approaches have gained increasing attention as potential strategies to enhance osteointegration and promote more physiological tissue healing. Before clinical application, these materials must undergo rigorous in vitro biological evaluation in accordance with international standards, particularly ISO 10993-5 for cytotoxicity assessment. The study will investigate cytotoxicity, cell viability, inflammatory responses, pro-fibrotic effects, and osteogenic potential using relevant human cell models. The regenerative effects of platelet-rich plasma (PRP), a source of growth factors, will also be evaluated. The biomaterials under investigation include a titanium alloy and polylactic acid (PLA), both widely used in orthopedic applications. The main objective is to demonstrate their biocompatibility, absence of cytotoxic, inflammatory, and pro-fibrotic effects, and their ability to support osteogenic processes and tissue integration. The findings will provide essential evidence for subsequent preclinical in vivo studies and future clinical translation.

Interventions

None listed

Sponsors

Stefano Zaffagnini
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

Femoral condyle, tibial plateau and synovial membrane samples Patients undergoing primary total knee arthroplasty at the Orthopaedic and Trauma Clinic II of the IRCCS Istituto Ortopedico Rizzoli (Bologna, Italy), in whom collection of tibial plateau, femoral condyles and/or synovial tissue is planned. Inclusion criteria: Age 18-80 years, male or female Primary tricompartmental osteoarthritis Body Mass Index (BMI) \< 35 Kellgren-Lawrence grade III-IV osteoarthritis Written informed consent

Exclusion criteria

Previous partial knee arthroplasty or cartilage repair/regenerative procedures Rheumatoid arthritis or chronic corticosteroid/immunosuppressive therapy Positive testing for HIV, HBV or HCV infection Concentrated bone marrow (BMC) samples Patients of both sexes providing written informed consent and presenting with the following characteristics: Inclusion criteria: Age 18-70 years Medial compartment knee osteoarthritis (Kellgren-Lawrence grade II-III for \>4 months) Failure of ≥6 months of conservative treatment (NSAIDs/analgesics, hyaluronic acid, corticosteroid or PRP injections) Written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Cellular health parameters72 hoursCellular health parameters were assessed after 72 hours of exposure to the materials and compared with standardized control samples

Secondary

MeasureTime frameDescription
Pro-inflammatory cytokines48 hoursLevels of pro-inflammatory cytokines were measured after 6, 24 and 48 hours of exposure to the materials
ROS48 hoursMarkers of oxidative stress were evaluated after 72 hours of exposure to the materials
Osteogenic potential28 daysOsteogenic potential was assessed by evaluating the gene expression of specific osteogenic markers and the production of protein biomarkers (ALP and P1NP) at 7, 14, and 28 days

Countries

Italy

Contacts

CONTACTstefano zaffagnini
stefano.zaffagnini@unibo.it0516366075

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026